Alterity Therapeutics (NASDAQ:ATHE) Upgraded at Zacks Research

Zacks Research upgraded shares of Alterity Therapeutics (NASDAQ:ATHE) to a hold rating in a research note published on Thursday,Zacks.com reports.

Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group assumed coverage on shares of Alterity Therapeutics in a research report on Wednesday, December 17th. They issued a “speculative buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold”.

Alterity Therapeutics Stock Down 0.6%

ATHE stock opened at $3.49 on Thursday. Alterity Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $7.00. The firm’s 50-day simple moving average is $3.27 and its 200 day simple moving average is $4.04.

Institutional Trading of Alterity Therapeutics

Several large investors have recently modified their holdings of ATHE. Greenleaf Trust grew its position in shares of Alterity Therapeutics by 88.2% during the 3rd quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock valued at $120,000 after acquiring an additional 15,000 shares during the period. Citadel Advisors LLC bought a new position in shares of Alterity Therapeutics in the 3rd quarter valued at about $83,000. HB Wealth Management LLC purchased a new position in shares of Alterity Therapeutics in the 3rd quarter worth approximately $220,000. Finally, Twin Lakes Capital Management LLC raised its stake in shares of Alterity Therapeutics by 2,250.3% in the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after acquiring an additional 133,333 shares during the period. Institutional investors own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.